RELATIONSHIP BETWEEN APOPTOSIS MARKERS(P53, BCL-2, BAX) AND CLINICAL-MORPHOLOGICAL PARAMETERS AND SURVIVAL IN NON-SMALL CELL LUNG CANCER
Abstract
The purpose of the study was to analyze the relationship between expression of the р53, bcl-2 and bax genes and clinical-morphological parameters and survival in patients with non-small cell lung cancer (NSCLC). Expression of bcl-2 and р53 was found to be higher in patients with squamous cell carcinoma, bax expression was higher in patients with adenocarcinoma and bcl-2 level was higher in patients with stage I NSCLC and in patients having no lymph node metastases. Survival of patients with NSCLC depended on the expression of p53, bcl-2 and depended no on the bax expression. Survival rates were increased in bcl-2 expression and decreased in p63 expression. Survival rate of patients with NSCLC was higher in –p53/+bcl-2 and –p53/+bcl-2/–bax immune phenotypes and lower in +p53/+bax and +p53/–bcl-2/+bax immune phenotypes. The unifactor regression analysis showed that bcl-2 and р53 were prognostic factors. The multifactor regression analysis revealed no relationship between bcl-2, р53, bax and prognosis of NSCLC.
About the Authors
D. S. Kobyakov
Kogalym Municipal Hospital, Kogalym
Russian Federation
Russian Federation
А. F. Lazarev
Altai branch of the N.N. Blokhin Russian Cancer Research Center, RAMS, Barnaul
Russian Federation
Russian Federation
Е. L. Lushnikova
Research Institute of Regional Pathology and Pathomorphology of Siberian Division of the Russian Academy of Medical Scienсеs, Novosibirsk
Russian Federation
19, Molodezhnaya Street, 628480-Kogalym, Tyumen region
Russian Federation
19, Molodezhnaya Street, 628480-Kogalym, Tyumen region
L. M. Nepomnyashchikh
Research Institute of Regional Pathology and Pathomorphology of Siberian Division of the Russian Academy of Medical Scienсеs, Novosibirsk
Russian Federation
19, Molodezhnaya Street, 628480-Kogalym, Tyumen region
Russian Federation
19, Molodezhnaya Street, 628480-Kogalym, Tyumen region
References
1. Apolinario R.M., van der Valk P., de Jong J.S., Deville W., van ArkOtte J., Dingemans A.M., van Mourik J.C., Postmus P.E., Pinedo H.M., Giaccone G. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected nonsmall-cell lung cancer // J. Clin. Oncol. 1997. Vol. 15 (6). Р. 2456–2466.
2. Borner M.M., Brousset P., Pfanner-Meyer B., Bacchi M., Vonlanthen S., Hotz M.A., Altermatt H.J., Schlaifer D., Reed J.C., Betticher D.C. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer // Br. J. Cancer. 1999. Vol. 79 (5–6). Р. 952–958.
3. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi M., Angeletti C.A., Basolo F., Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer // Br. J. Cancer. 1995. Vol. 71 (5). Р. 1003–1007.
4. Gessner C., Liebers U., Kuhn H., Stiehl P., Witt C., Schauer J., Wolff G. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer // Eur. Respir. J. 2002. Vol. 19 (1). Р. 134–140.
5. Gregorc V., Darwish S., Ludovini V., Pistola L., De Angelis V., Mihaylova Z., Bellezza G., Sidoni A., Cavaliere A., Bucciarelli E., Massaro G., Tonato M. The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer // Lung cancer. 2003. Vol. 42 (3). Р. 275–281.
6. Groeger A.M., Esposito V., De Luca A., Cassandro R., Tonini G., Ambrogi V., Baldi F., Goldfarb R., Mineo T.C., Baldi A., Wolner E. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers // Histopathology. 2004. Vol. 44 (1). Р. 54–63.
7. Han H., Landreneau R.J., Santucci T.S., Tung M.Y., Macherey R.S., Shackney S.E., Sturgis C.D., Raab S.S., Silverman J.F. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer // Hum. pathol. 2002. Vol. 33 (1). Р. 105–110.
8. Ishida H., Irie K., Itoh T., Furukawa T., Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction // Cancer. 1997. Vol. 15 (6). Р. 1034–1045.
9. Jeong S.H., Lee H.W., Han J.H., Kang S.Y., Choi J.H., Jung Y.M., Choi H., Oh Y.T., Park K.J., Hwang S.C., Sheen S.S., Oh Y.J., Kim J.H., Lim H.Y. Low expression of Bax predicts poor prognosis in resected nonsmall cell lung cancer patients with non-squamous histology // Jpn. J. Clin. Oncol. 2008. Vol. 38 (10). Р. 661–669. doi: 10.1093/jjco/hyn089.
10. Lai R.S., Wang J.S., Hsu H.K., Chang H.C., Lin C.H., Lin M.H. Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer // Jpn. J. Clin. Oncol. 2002. Vol. 32 (10). Р. 393–397.
11. Lee J.S., Yoon A., Kalapurakal S.K., Ro J.Y., Lee J.J., Tu N., Hittelman W.N., Hong W.K. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor // J. Clin. Oncol. 1995. Vol. 13 (8). Р. 1893–1903.
12. Martin B., Paesmans M., Berghmans T., Branle F., Ghisdal L., Mascaux C., Meert A.P., Steels E., Vallot F., Verdebout J.M., Lafitte J.J., Sculier J.P. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis // Br. J. Cancer. 2003. Vol. 89 (1). Р. 55–64.
13. Moldvay J., Scheid P., Wild P., Nabil K., Siat J., Borrelly J., Marie B., Farre G., Labib T., Pottier G., Sesboue R., Bronner C., Vignaud J.M., Martinet Y., Martinet N. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma // Clin. Cancer Res. 2000. Vol. 6 (3). Р. 1125–1134.
14. Ohsaki Y., Toyoshima E., Fujiuchi S., Matsui H., Hirata S., Miyokawa N., Kubo Y., Kikuchi K. bcl-2 and p53 protein expression in nonsmall cell lung cancers: correlation with survival time // Clin. Cancer Res. 1996. Vol. 2 (5). Р. 915–920.
15. Poleri C., Morero J.L., Nieva B., Vazquez M.F., Rodriguez C., de Titto E., Rosenberg M. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis // Chest. 2003. Vol. 123 (6). Р. 1858–1867. 16. Shibata Y., Hidaka S., Tagawa Y., Nagayasu T. Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer // Anticancer res. 2004. Vol. 24 (3b). Р. 1925–1928.
16. Steels E., Paesmans M., Berghmans T., Branle F., Lemaitre F., Mascaux C., Meert A.P., Vallot F., Lafitte J.J., Sculier J.P. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis // Eur. Respir. J. 2001. Vol. 18 (4). Р. 705–719.
17. TNM classification of malignant tumours / Eds. L. Sobin, M. Gospodarowicz, C. Wittekind. 7th edition. Oxford: Wiley-Blackwell, 2009. Р. 138–146.
18. Tomizawa Y., Kohno T., Fujita T., Kiyama M., Saito R., Noguchi M., Matsuno Y., Hirohashi S., Yamaguchi N., Nakajima T., Yokota J. Correlation between the status of the p53 gene and survival in patients with stage I nonsmall cell lung carcinoma // Oncogene. 1999. Vol. 18 (4). Р. 1007–1014.
19. Yaren A., Oztop I., Kargi A., Ulukus C., Onen A., Sanli A., Binicier O., Yilmaz U., Alakavuklar M. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis // Int. J. Clin. Pract. 2006. Vol. 60 (6). Р. 675–682.
20. Zhu C.Q., Shih W., Ling C.H., Tsao M.S. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation // J. Clin. Pathol. 2006. Vol. 59 (8). Р. 790–800.
Review
For citations:
Kobyakov D.S., Lazarev А.F., Lushnikova Е.L., Nepomnyashchikh L.M. RELATIONSHIP BETWEEN APOPTOSIS MARKERS(P53, BCL-2, BAX) AND CLINICAL-MORPHOLOGICAL PARAMETERS AND SURVIVAL IN NON-SMALL CELL LUNG CANCER. Siberian journal of oncology. 2014;(5):10-16. (In Russ.)
Views:
864
Email this article 
